Spots Global Cancer Trial Database for transarterial chemoembolization
Every month we try and update this database with for transarterial chemoembolization cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TACE Combined With Penpulimab and Anlotinib for Advanced HCC | NCT05344924 | Hepatocellular ... | TACE+penpulimab... | 18 Years - 80 Years | Zhongda Hospital | |
| International Registry on Cholangiocarcinoma Treatment | NCT01920503 | Cholangiocarcin... | Doxorubicin | 18 Years - 75 Years | International Group of Endovascular Oncology | |
| TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | NCT04992143 | BCLC Stage C He... | TACE Tilelizumab Sorafenib | 18 Years - | First Affiliated Hospital of Zhejiang University | |
| Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma | NCT03895359 | Hepatocellular ... | Stereotactic Bo... Transarterial C... | 18 Years - | Lawson Health Research Institute | |
| Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC | NCT02018757 | Carcinoma, Hepa... | TACE containing... TACE containing... | 18 Years - 75 Years | First Hospital of China Medical University | |
| Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System | NCT02525952 | Hepatocellular ... | Hepatectomy TACE | 18 Years - 70 Years | Eastern Hepatobiliary Surgery Hospital | |
| TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma (IDADOX) | NCT06114082 | Hepatocellular ... Liver Cancer | IDA-TACE DOX-TACE | 19 Years - | Seoul National University Hospital | |
| TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma | NCT01721941 | Hepatocellular ... | Phase I Dose le... Phase I dose le... Phase I Dose le... Phase I Dose le... | 18 Years - | Scripps Clinic Cancer Center | |
| TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer | NCT03732235 | Liver Metastasi... | TACE+ systemic ... FOLFIRI+Bevaciz... TACE | 18 Years - | International Group of Endovascular Oncology | |
| Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma | NCT00844883 | Hepatocellular ... Hepatoma | sorafenib LC Bead-TACE | 18 Years - | Yale University | |
| Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison | NCT04823715 | Non-metastatic ... | TACE + hypofrac... Surgical resect... | 18 Years - | Hospices Civils de Lyon | |
| The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma | NCT03652467 | Hepatocellular ... | Conventional TA... Deferoxamine an... | 18 Years - | Jinan Military General Hospital | |
| Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC | NCT04143191 | Hepatocellular ... | Sorafenib Transarterial c... | 18 Years - 75 Years | Sun Yat-sen University | |
| The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | NCT00827554 | Hepatocellular ... | LMWH TACE | 18 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
| Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers | NCT05278195 | Hepatocellular ... | 18 Years - | Zhongda Hospital | ||
| TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong) | NCT04560751 | Carcinoma, Hepa... | Lenvatinib TACE | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | NCT00827554 | Hepatocellular ... | LMWH TACE | 18 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
| Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC | NCT02018757 | Carcinoma, Hepa... | TACE containing... TACE containing... | 18 Years - 75 Years | First Hospital of China Medical University | |
| Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC | NCT04174781 | Hepatocellular ... | Sintilimab DEB-TACE | 18 Years - 75 Years | Zhejiang University | |
| Safety and Efficacy of "Immuncell-LC" in TACE Therapy | NCT02856815 | Carcinoma, Hepa... | Immuncell-LC | 20 Years - 80 Years | GC Cell Corporation | |
| Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma | NCT05416073 | Hepatocellular ... Transarterial C... Hepatic Arteria... Pain | Esketamine Sufentanil | 18 Years - 80 Years | The Second Affiliated Hospital of Chongqing Medical University | |
| A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC | NCT01997957 | Hepatocellular ... | S-1 | 18 Years - 80 Years | Peking University Cancer Hospital & Institute | |
| Perioperative Therapy for Hepatocellular Carcinoma | NCT04653389 | Hepatocellular ... | Sintilimab Inje... TACE Radiotherapy | 18 Years - 75 Years | Zhejiang University | |
| TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC | NCT04597970 | Transarterial C... Hepatocellular ... | cTACE-HAIC | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT | NCT04127396 | Carcinoma, Hepa... Portal Vein Tum... | Lenvatinib Pill Transarterial c... Sorafenib Transarterial c... | 18 Years - 75 Years | Beijing Ditan Hospital | |
| A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | NCT04981665 | Hepatocellular ... Adjuvant Therap... | Tislelizumab TACE | 18 Years - | Zhejiang University | |
| TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC | NCT05332821 | Hepatocellular ... | PD-1/PD-L1 inhi... TACE | 18 Years - | Zhongda Hospital | |
| Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT02507765 | Child-Pugh Clas... Child-Pugh Clas... Stage IIIA Hepa... Stage IIIB Hepa... Stage IIIC Hepa... Stage IVA Hepat... Stage IVB Hepat... | Laboratory Biom... Stereotactic Bo... Transarterial C... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC | NCT06001567 | Thrombocytopeni... Hepatocellular ... | Avatrombopag | 18 Years - | Second Affiliated Hospital of Guangzhou Medical University | |
| The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma | NCT05862181 | Advanced Hepato... | DEB-TACE plus H... | 18 Years - | Peking University Cancer Hospital & Institute | |
| Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT | NCT04127396 | Carcinoma, Hepa... Portal Vein Tum... | Lenvatinib Pill Transarterial c... Sorafenib Transarterial c... | 18 Years - 75 Years | Beijing Ditan Hospital | |
| Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma | NCT02616926 | Hepatocellular ... | Hepatic resecti... TACE RFA | 18 Years - 65 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT | NCT04967495 | Hepatocellular ... | TACE combined w... TACE combined w... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC | NCT04967482 | Hepatocellular ... | Drug-eluting be... Conventional tr... | 18 Years - 70 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC | NCT04597970 | Transarterial C... Hepatocellular ... | cTACE-HAIC | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization | NCT05390112 | Circulating Tum... Hepatocellular ... Transarterial C... | DNA | 18 Years - | University Hospital, Rouen | |
| Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma | NCT01676194 | Hepatocellular ... | Intra-arterial ... | 18 Years - | Rennes University Hospital | |
| TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC | NCT05332496 | Hepatocellular ... | PD-1/PD-L1 inhi... TACE | 18 Years - | Zhongda Hospital | |
| Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma | NCT03614546 | Primary Hepatoc... | SBRT IMRT Hepatectomy TACE | 18 Years - 80 Years | The Third Xiangya Hospital of Central South University | |
| Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | NCT04472767 | Hepatocellular ... HCC | Nivolumab Ipilimumab Cabozantinib Transarterial C... | 18 Years - | University of California, Irvine | |
| Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | NCT04472767 | Hepatocellular ... HCC | Nivolumab Ipilimumab Cabozantinib Transarterial C... | 18 Years - | University of California, Irvine | |
| The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma | NCT03652467 | Hepatocellular ... | Conventional TA... Deferoxamine an... | 18 Years - | Jinan Military General Hospital | |
| Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation | NCT04813861 | Hepatocellular ... | 18 Years - | Central Hospital, Nancy, France | ||
| HepaSphere™ Microspheres Prospective Registry | NCT04866290 | Metastatic Colo... | HepaSphere Micr... | - | Merit Medical Systems, Inc. | |
| Survival Analysis: TACE vs. Combination Therapy in HCC | NCT06261138 | Hepatocellular ... | Transarterial c... Systemic treatm... | 18 Years - 75 Years | Zhejiang University | |
| Perioperative Therapy for Hepatocellular Carcinoma | NCT04653389 | Hepatocellular ... | Sintilimab Inje... TACE Radiotherapy | 18 Years - 75 Years | Zhejiang University | |
| Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma | NCT05280444 | Hepatocellular ... | Idarubicin Hydr... | 18 Years - 75 Years | Zhongda Hospital | |
| Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer | NCT01042041 | Hepatocellular ... Liver Cancer Localized Unres... | sorafenib tosyl... doxorubicin hyd... cisplatin mitomycin C transarterial c... hepatic artery ... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion | NCT01857726 | Hepatocellular ... | Doxorubicin Cisplatin | 18 Years - 80 Years | Seoul National University Hospital | |
| TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma | NCT04103398 | Hepatocellular ... Sorafenib Transarterial C... | TACE+sorafenib TACE | 18 Years - 75 Years | Sun Yat-sen University | |
| Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma | NCT01677468 | Hepatocellular ... Transarterial C... | Intermediate em... Complete emboli... | 19 Years - | Hallym University Medical Center | |
| TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma | NCT04490694 | Hepatocellular ... | Lenvatinib TACE | 18 Years - | Shanghai Zhongshan Hospital | |
| HepaSphere™ Microspheres Prospective Registry | NCT04866290 | Metastatic Colo... | HepaSphere Micr... | - | Merit Medical Systems, Inc. | |
| Survival Analysis: TACE vs. Combination Therapy in HCC | NCT06261138 | Hepatocellular ... | Transarterial c... Systemic treatm... | 18 Years - 75 Years | Zhejiang University | |
| TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC | NCT03782831 | Hepatocellular ... | TACE PD-1 antibody Placebos | 18 Years - 75 Years | Sun Yat-sen University | |
| Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) | NCT01318200 | Recurrent Hepat... | Transarterial C... CyberKnife SBRT | 18 Years - | Accuray Incorporated | |
| SBRT or TACE for Advanced HCC | NCT03338647 | Hepatocellular ... | DEB SBRT | 18 Years - 75 Years | University of Aarhus | |
| Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma | NCT02616926 | Hepatocellular ... | Hepatic resecti... TACE RFA | 18 Years - 65 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | NCT05776875 | Hepatocellular ... BCLC Stage B He... | Atezolizumab In... Bevacizumab Transarterial c... | 18 Years - | Yale University | |
| 3T MRI to Predict TACE Response of HCC | NCT02070822 | Carcinoma, Hepa... | 20 Years - | National Taiwan University Hospital | ||
| Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver | NCT02724540 | Neuroendocrine ... Liver Metastase... | Bland Embolizat... Transarterial c... Drug Eluting Be... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma | NCT02755311 | Hepatocellular ... | liver resection transarterial c... carboplatin lipiodol epirubicin , pi... absorbable gela... | 18 Years - 75 Years | Sun Yat-sen University | |
| TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases) | NCT03783559 | Colorectal Aden... | TACE chemotherapy±ta... | 18 Years - 75 Years | Fudan University | |
| Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy (SBRT) in Hepatocellular Carinoma | NCT03079778 | Hepatocellular ... | transarterial c... TACE plus RT | 18 Years - 95 Years | Lawson Health Research Institute | |
| DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC | NCT06397235 | Hepatocellular ... | DEB-TACE+HAIC DEB-TACE | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors | NCT06261814 | Liver Neoplasms | Sulfur Hexafluo... Contrast-Enhanc... Transarterial C... Medical Chart R... | 18 Years - | Thomas Jefferson University | |
| CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302) | NCT05704192 | Hepatocellular ... Portal Hyperten... | TACE ± Systemic... | 18 Years - | Zhongda Hospital | |
| Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma | NCT02006030 | Unresectable He... | ADI-PEG 20 Transarterial c... | 18 Years - | Polaris Group | |
| Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC | NCT02338297 | Carcinoma, Hepa... | TACE EGM PVA | 18 Years - | Nanjing Medical University | |
| Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study | NCT04975932 | Hepatocellular ... | TACE+ICIs TACE | 18 Years - | Zhongda Hospital | |
| Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization | NCT02762266 | Child-Pugh Clas... Child-Pugh Clas... Recurrent Hepat... | Stereotactic Bo... Transarterial C... embolic agent lipiodol | 18 Years - | Stanford University | |
| Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma | NCT02525380 | Hepatocellular ... | Device(DC Bead) | 18 Years - 80 Years | Seoul National University Hospital | |
| Survival Analysis: TACE vs. Combination Therapy in HCC | NCT06261138 | Hepatocellular ... | Transarterial c... Systemic treatm... | 18 Years - 75 Years | Zhejiang University | |
| DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma | NCT04834674 | Intrahepatic Ch... Transarterial C... Apatinib PD-1 Antibody | DEB-TACE combin... | 18 Years - 80 Years | Sichuan Cancer Hospital and Research Institute | |
| TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC | NCT05332496 | Hepatocellular ... | PD-1/PD-L1 inhi... TACE | 18 Years - | Zhongda Hospital | |
| Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization | NCT04780789 | Hepatocellular ... Hepatocellular ... | Transarterial C... | 18 Years - | Brno University Hospital | |
| Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC) | NCT05361161 | Gastric Cancer Embolization | Transarterial C... | 18 Years - 80 Years | The First Affiliated Hospital of Zhengzhou University | |
| ISP-TACE Versus TACE for HCC With PVTT | NCT03108248 | HCC Portal Vein Tum... | ethiodized oil;... stent; idoine-1... | 20 Years - 75 Years | Zhongda Hospital | |
| TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial | NCT04531228 | Hepatocellular ... Transarterial C... | TACE-HAIC plus ... | 17 Years - 85 Years | Sun Yat-sen University | |
| Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma | NCT00857805 | Carcinoma, Hepa... | Transarterial C... Proton Beam Rad... | 18 Years - 80 Years | Loma Linda University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
